Effect of early prophylactic low-dose recombinant human erythropoietin on retinopathy of prematurity in very preterm infants.
Huiqing SunJuan SongWenqing KangYong WangXiantao SunChongchen ZhouHong XiongFalin XuMingchao LiXiaoli ZhangZengyuan YuXirui PengBingbing LiYiran XuShan XingXiaoyang WangChanglian ZhuPublished in: Journal of translational medicine (2020)
Repeated low-dose rhEPO administration has no significant influence on the development of ROP; however, it may be effective for type 2 ROP in infant boys or in infants with gestational age > 28 weeks and birth weight > 1500 g. Trial registration The data of this study were retrieved from two clinical studies registered ClinicalTrials.gov (NCT02036073) on January 14, 2014, https://clinicaltrials.gov/ct2/show/NCT02036073 ; and (NCT03919500) on April 18, 2019. https://clinicaltrials.gov/ct2/show/NCT03919500 .
Keyphrases
- gestational age
- birth weight
- low dose
- recombinant human
- preterm infants
- preterm birth
- image quality
- computed tomography
- high dose
- dual energy
- weight gain
- low birth weight
- contrast enhanced
- clinical trial
- study protocol
- magnetic resonance imaging
- phase iii
- randomized controlled trial
- big data
- physical activity
- machine learning
- body mass index
- double blind